The US Bankruptcy Court granted an order for the extension of the exclusivity periods for Sorrento Therapeutics, Inc. on December 18, 2023. As per the order, the debtor?s exclusivity period to file its plan and to solicit votes on its plan, have been extended by 42 days i.e. up to January 8, 2024 and March 8, 2024, respectively.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0137 USD | -31.50% | -31.50% | -88.91% |
Mar. 15 | Scilex Settles Claims in Case Against Virpax for $6 Million, 6% Royalties From Three Drugs | MT |
Mar. 12 | News Highlights : Top Company News of the Day - Tuesday at 5 AM ET | DJ |
1st Jan change | Capi. | |
---|---|---|
-88.91% | 7.45M | |
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.74B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |
- Stock Market
- Equities
- SRNE Stock
- News Sorrento Therapeutics, Inc.
- Fifth Motion for Exclusivity Period Extension Approved For Sorrento Therapeutics, Inc.